jesperbalslev.dk
Jesper Balslev | Foredrag & publikationer & presse
http://www.jesperbalslev.dk/foredrag-artikler
Mdash; et menneske i verden. Foredrag & publikationer & presse. Foredrag & publikationer & presse. Prosa: Tre bud på teknologikritisk sommerlæsning. Samtale med Anders Hvid, 2015). 8211; dansk bog vil reducere os alle til flade teknologikonsumenter i en problemfri verden (boganmeldelse, 2015). Radio24syv: Om Apples af lancering nye produkter (2014). Information: Magten til masserne anno 2014. Kommunikationsforum: Fra social media til cross media. Kommunikationsforum: To save everything, click here. Leven...
kalvista.com
KalVista Pharmaceuticals Ltd -
http://kalvista.com/about/overview.php
UK: 44 (0)1980 753002. USA: 1 (857) 241 3897. Creating a new generation of small molecule protease inhibitors. KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs. The Company features an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in dis...
kalvista.com
KalVista Pharmaceuticals Ltd - Senior Management
http://kalvista.com/about/investors.php
UK: 44 (0)1980 753002. USA: 1 (857) 241 3897. Creating a new generation of small molecule protease inhibitors. RA Capital’s scientifically trained research team is intensely data driven in its continual effort to identify early breakthroughs and originate conviction in new ideas. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, public market dynamics, and many other fact...
kalvista.com
KalVista Pharmaceuticals Ltd - News Article
http://www.kalvista.com/press/articles/KalVista-Pharmaceuticals-Raises-33-Million-Dollars-to-Advance-Development-of-Novel-Plasma-Kallikrein-Inhibitors-in-DME-and-HAE.php
UK: 44 (0)1980 753002. USA: 1 (857) 241 3897. Creating a new generation of small molecule protease inhibitors. KalVista Pharmaceuticals Raises $33 Million to Advance Development of Novel Plasma Kallikrein Inhibitors in Diabetic Macular Edema and Hereditary Angioedema. Boston, MA, USA and Salisbury, UK. 22 July 2015. KalVista is also rapidly advancing orally delivered inhibitors through pre-clinical testing. These drugs will not only expand the therapeutic options for DME patients but also enable KalV...
pcovery.com
Investors - PCOVERY
http://pcovery.com/index.php/about-pcovery/investors
Pcovery was founded in 2009 aided by a pre-Seed grant from Novo Seeds. The first Seed round was made in 2010 by Østjysk Innovation and Novo Seeds. In 2013 a second Seed round was made by the existing investors. Also in 2013 Pcovery received a Seeding Drug Discovery Award of up to 3.7 m from the Wellcome Trust. Boehringer Ingelheim Venture Fund. The Boehringer Ingelheim Venture Fund was formed in March 2010 to invest in biotechnology and start-up companies to help drive innovation in medical science. ...
tarveda.com
Tarveda Therapeutics | Investors
http://www.tarveda.com/investors.html
Benefits of Miniaturized Biologic Drug Conjugates. NanoDimension is a venture capital firm committed to building companies developing market-disruptive technologies on the nano scale. Founded in 2002, and with offices in Europe and the United States, NanoDimension focuses on early to mid-stage investments across business sectors. Novo A/S is a private limited liability company fully owned by the Novo Nordisk Foundation. For further information visit www.novo.dk. Manages two dedicated life sciences and he...
copenhagenspin-outs.dk
Partnere - Copenhagen Spin-outs
http://www.copenhagenspin-outs.dk/partnere
Københavns Universitet er den største institution for forskning og uddannelse i Danmark med 38.000 studerende og 9.000 ansatte. I 2005 blev universitetet valgt som årets entrepreneurship-universitet. Københavns Universitet havde i 2010 mere end 300 forskningsaftaler med virksomheder. E-mail: inno@adm.ku.dk. Læs mere om KU. Danmarks Tekniske Universitet (DTU). Afdeling for Innovation og Sektorudvikling. Anker Engelundsvej 1, bygn. 101 A. 2800 Kgs. Lyngby. Tlf 45 25 71 65. Mail: myndighed@adm.dtu.dk. Medic...
diabposition.blogspot.com
Diabetes: September 2011
http://diabposition.blogspot.com/2011_09_01_archive.html
DIABETES CIES SEARCH ENGINE [SELECTED WEBSITES]. Bristol-Myers Squibb and Ambrx : Collaboration for. Kuros : Patient Recruitment in a Phase IIb Clinica. KalVista Pharmaceuticals Launched with £8 Million . Lpath Addresses Diabetic Neuropathic Pain With Fin. Monday, September 26, 2011. Bristol-Myers Squibb and Ambrx : Collaboration for Novel Biologics Programs in Diabetes and Heart Failure. September 22, 2011 - Bristol-Myers Squibb Company (NYSE: BMY). And Ambrx, Inc. Relaxin is a naturally occurring hormo...